Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)-Reference-Cited by-同舟云学术

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)

Published:2014-02 Issue:2 Volume:83 Page:174-181
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Yang James Chih-Hsin,Wu Yi-Long,Chan Valorie,Kurnianda Johan,Nakagawa Kazuhiko,Saijo Nagahiro,Fukuoka Masahiro,McWalter Gael,McCormack Rose,Mok Tony S.K.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2009

2. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2011

3. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC);Kris;J Clin Oncol,2011

4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol,2011

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Somatic mutation: Pharmacogenomics in oncology care;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer;Technology in Cancer Research & Treatment;2023-01

3. Corrigendum;Technology in Cancer Research & Treatment;2023-01

4. Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation;Frontiers in Oncology;2022-11-08

5. Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation;Frontiers in Pharmacology;2022-08-26